"two weeks away from published results".......on their favipiravir out patient trial .... 856 participants.
If positive...immediate EU FDA Approval. Could be explosive to the share price.
This is the first in front of the FDA on mild to moderate Covid symptoms
https://stockhouse.com/news/press-releases/2020/09/11/appili-submits-protocol-for-a-phase-3-study-evaluating-favipiravir-for-the
Also "In a sub study, researchers intend to further examine 136 trial participants to evaluate favipiravir’s effect on viral shedding. This occurs when the virus is contagious, replicating inside the body, and is released into the environment. In this portion of the study, investigators are seeking to determine if treatment with favipiravir can shorten the period of viral shedding, thus diminishing the period of infectivity and decreasing the spread of the virus."
MM